Vestal Point Capital’s GeneDx Holdings WGS Stock Holding History

Vestal Point Capital’s Portfolio WGS Stock Details WGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-250,000	Closed	-$16.1M	–	97
2026 Q1	$16.1M	Buy	+250,000	New	+$22.8M	0.45%	56

Other funds holding WGS

Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Vestal Point Capital's WGS Position: Q2 2026 in Review

Vestal Point Capital sold out of GeneDx Holdings (WGS) in Q2 2026, closing a stake of 250,000 shares — an estimated $16.1M sold.

Vestal Point Capital first reported a position in WGS in Q1 2026 and held it in 1 quarter. The position peaked at $16.1M in Q1 2026. 223 funds tracked by Wall St. Rank hold WGS as of Q2 2026.

Vestal Point Capital reported no remaining GeneDx Holdings position as of Q2 2026 after selling out during the quarter.
Vestal Point Capital sold 250,000 GeneDx Holdings shares in Q2 2026, an estimated $16.1M.
Vestal Point Capital first reported a position in GeneDx Holdings in Q1 2026 and held it in 1 quarter.
Vestal Point Capital's GeneDx Holdings position peaked at $16.1M in Q1 2026.
223 funds tracked by Wall St. Rank held GeneDx Holdings as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.